Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.

Lara, Primo N; Law, Lisa Y; Wright, John J; Frankel, Paul; Twardowski, Przemyslaw; Lenz, Heinz Josef; Lau, Derick H M; Kawaguchi, Tomoya; Gumerlock, Paul H; Doroshow, James H; Gandara, David R

Lara, Primo N; Law, Lisa Y; Wright, John J; Frankel, Paul; Twardowski, Przemyslaw; Lenz, Heinz Josef; Lau, Derick H M; Kawaguchi, Tomoya; Gumerlock, Paul H; Doroshow, James H; Gandara, David R.

Affiliation

Lara PN; University of California, Davis Cancer Center, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu

Anticancer Drugs ; 16(3): 317-21, 2005 Mar.

Article in En | MEDLINE | ID: mdl-15711184

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinolones / Neoplasms Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2005 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Search on Google

Add to My VHL

XML

PubMed Links